DE-GEMPHARMATECH
25.4.2022 14:32:08 CEST | Business Wire | Press release
GemPharmatech LLC is pleased to announce that on April 25, 2022, its parent company, GemPharmatech Co., Ltd., went public on the STAR MARKET of the Shanghai Stock Exchange under the stock code 688046. The initial offering included 50,000,000 ordinary shares at a public offering price of￥22.53 ($3.51) per share.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005235/en/
GemPharmatech, established on December 29, 2017, is a high-tech enterprise specializing in the research and development of laboratory animal models, production, technical services, and upstream and downstream industry expansion. In order to meet the rapid development needs of biomedical research and new drug development, the company has constructed more than 20,000 commercial mouse models with independent intellectual property rights, becoming the world's largest collection of mouse strains. These models promote research and development breakthroughs in the fields of gene function identification, disease mechanism analysis, drug target discovery, drug efficacy screening and verification, and provides a solution to the bottleneck of animal model technology. GemPharmatech has established subsidiaries in Beijing, Foshan, Chengdu, Changzhou, Guangzhou, and Shanghai, as well as a US subsidiary, GemPharmatech LLC. The company’s facilities include 30,000+ square meters of SPF-level facilities.
Models That Defy the Impossible
According to Dr. Xiang Gao, founder and Chairman of GemPharmatech Co. Ltd., “GemPharmatech will take this issuance and listing as an opportunity to keep up with the frontier trends of life science and new drug development, adhere to an R&D-driven strategy, continuously optimize the laboratory animal construct strategy and genetic engineering technology, and improve our preclinical service capabilities.”
“GemPharmatech will use the funds raised by the IPO for investment in key projects such as launching a germ-free mouse platform, and to further expand global market share and influence,” says US CEO Dr. Mark Moore. “The company is committed to providing the best service to our customers, promoting the development of the biopharmaceutical industry, and repaying the society, employees and investors through excellent business performance.”
About GemPharmatech
GemPharmatech is a leading provider of animal models and services to the global preclinical R&D community. We specialize in developing animal models using cutting edge gene-editing technologies with a large collection of cKO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficient mice, and germ-free mice. GemPharmatech provides an expansive array of preclinical services, including mouse model customization, pharmacology services such as drug efficacy testing, and customized breeding. The company has developed one of the world's largest collections of mouse models to enable scientific innovation and accelerate drug development. Learn more at gempharmatech.us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005235/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering11.5.2026 21:49:00 CEST | Press release
INNIO Group ("INNIO"), a leading global distributed energy solutions provider, today announces that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its common shares. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511389675/en/ INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined. INNIO has applied to list its common shares on the Nasdaq Global Select Market under the ticker symbol "INIO." Goldman Sachs & Co. LLC, J.P. Morgan and Morgan Stanley are acting as joint lead book-running managers for the proposed offering. BofA Securities, Barclays and Citigroup are acting as book-running managers for the proposed offering. Baird, BNP Paribas
Only 7% of Companies Achieve Full Compliance as Global Expansion Increases Legal Complexity11.5.2026 15:00:00 CEST | Press release
47% of general counsels say beneficial ownership rules pose the biggest risks to legal operations44% lack confidence in meeting cross-border data security requirements As businesses accelerate their global expansion in 2026, compliance fails to keep pace. In fact, only 7% of organizations report full compliance across their global entities, according to a new study by CSC, the leading provider of global business administration and compliance solutions. CSC surveyed 350 general counsel (GCs) and senior legal professionals across Europe, North America, and Asia Pacific to examine how their teams navigate international expansion, regulatory pressure, and the increasing adoption of artificial intelligence (AI).¹ The findings appear in CSC’s latest report, General Counsel Barometer 2026: From Complexity to Control. Most organizations report partial compliance, with over half (53%) estimating they are 50–75% compliant, and a further 35% placing themselves between 76%–99%. This leaves just 7%
IFF Opens Vanilla Innovation Center in Madagascar11.5.2026 14:15:00 CEST | Press release
Advancing science‑led flavor innovation where vanilla is grown IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health & bioscience—today announced the opening of its Vanilla Innovation Center in Madagascar, reinforcing vanilla as a strategic and priority tonality for IFF and strengthening its ability to innovate at origin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260508110162/en/ IFF's Vanilla Innovation Center in Madagascar “The opening of the center marks an important step in how we approach vanilla innovation,” said Adam Jańczuk, Ph.D., senior vice president, research, creation and design, Taste, IFF. “By strengthening our presence at origin, we connect science, creativity and sustainability more closely, responding to climate changes, safeguarding quality and creating value across the supply chain.” Located in Toamasina, Madagascar’s principal seaport, near vanilla growing areas and post‑h
ARIS Recognised as a Leader in Gartner® Magic Quadrant™ for Process Intelligence Platforms, Believes This Reinforces Its Role in Enabling Enterprise AI at Scale11.5.2026 14:00:00 CEST | Press release
ARIS, the process context foundation platform for enterprise AI deployment, today announced its recognition as a Leader in the Gartner® Magic Quadrant™ for Process Intelligence Platforms. This is the fourth consecutive year that ARIS has been recognized as a Leader in the report and the company believes it underscores a continued commitment to innovation and growth as enterprises focus on turning AI ambition into measurable business outcomes. While technology has advanced rapidly, companies are struggling to operationalise AI across complex operating models. ARIS sees this recognition by Gartner as a reflection of its strength in delivering a single unified platform for process intelligence, providing the context layer on which G2000 organisations can successfully deploy and scale agentic AI. “AI is moving from experimentation to execution – but many enterprises are finding it difficult to scale,” said Guillaume Bacuvier, CEO of ARIS. “The reason is simple: AI lacks the context it need
HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors11.5.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has submitted a De Novo request to the U.S. Food and Drug Administration seeking authorization to expand the use of its Edison® Histotripsy System to include the destruction of kidney (renal) tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511268688/en/ HistoSonics Edison® Histotripsy System This milestone marks a significant step forward in the company’s mission to transform the treatment of solid tumors with a completely non-invasive technology that harnesses focused ultrasound to mechanically liquefy and destroy targeted tissue, reducing the risk of many complications and side effects associated with surgery, radiation, and other common therapies. “This submission is an important milestone in expanding histotripsy beyond the liver and into the kidney, an area where patients and physicians are s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom